Mutated HIV-1 gp120 polypeptides for conformational control
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current approaches to managing HIV infection, particularly with HAART, fail to fully restore health and are hindered by latent viral reservoirs, leading to re-emergence of viral replication and AIDS progression, and there is a lack of methods to induce specific conformations in the HIV Env protein for vaccine development and entry inhibitor design.
Innovation Solution
A composition comprising mutated HIV-1 gp120 polypeptides with specific substitutions and gp120 ligands that induce the Env protein into desired open or closed conformations, allowing for the elicitation of an immune response and the development of HIV vaccines and entry inhibitors.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If HAART is used to control HIV infection, then viral replication is suppressed and life expectancy increases, but latent viral reservoirs persist and health cannot be fully restored
Solution Approach 1:
The patent applies preliminary action by using mutated gp120 proteins in advance to stimulate the immune system to produce neutralizing antibodies before viral reservoirs can cause re-emergence. The composition is designed to preemptively enhance immune recognition of viral epitopes, creating immunological memory that can combat latent reservoirs when they become active.
Solution Approach 2:
The mutated gp120 protein serves as an intermediary between the immune system and the latent viral reservoirs. By presenting modified viral epitopes through this intermediary, the immune system can be trained to recognize and neutralize viral components without directly confronting the dormant reservoirs, thereby addressing the harmful factor while maintaining viral suppression.
2Adaptability or versatility
If standard gp120 is used for vaccine development, then immunogenicity is limited, but specific conformations needed for effective immune response cannot be induced
Solution Approach 1:
The patent applies parameter changes by systematically mutating specific amino acid residues in gp120 (positions 61, 105, 108, 375, 474, 475, and 476) to alter the protein's conformational parameters. These mutations stabilize desired conformations and enhance immunogenicity by making the protein more adaptable to presenting effective epitopes while maintaining structural reliability for immune recognition.
Solution Approach 2:
The patent creates modified copies of the native gp120 protein with specific mutations that replicate and enhance desirable conformational features. These copied and improved structures serve as immunogens that can induce more effective neutralizing antibodies compared to the standard gp120, thereby resolving the contradiction between conformational flexibility and immunogenicity.
3Reliability
If gp120 ligands are used to induce specific conformations, then Env protein becomes amenable to neutralization, but the complexity of identifying effective ligands increases
Solution Approach 1:
The patent applies preliminary action by pre-stabilizing specific conformations of the Env protein through gp120 mutations before introducing ligands. This preliminary conformational preparation simplifies the subsequent ligand identification process, as the protein is already in a more amenable state for neutralization, reducing the complexity of screening and characterizing effective ligands.
Data Source
AI summary
Compositions and methods based on the use of mutated HIV-1 gp120 polypeptides having amino acid substitutions at positions 61, 105, 108, 375, 474, 475 and 476 are described. These mutated HIV-1 gp120 polypeptides, which make the HIV env protein more amenable to adopt specific conformations when contacted with gp120 ligands, may be useful as vaccines or tools to identify and characterize agents modulating HIV infection.